Biohaven Ltd. (BHVN)

Market Cap	2.82B
Revenue (ttm)	n/a
Net Income (ttm)	-846.42M
Shares Out	102.05M
EPS (ttm)	-9.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,090,048
Open	28.25
Previous Close	28.39
Day's Range	26.70 - 28.44
52-Week Range	26.57 - 55.72
Beta	3.91
Analysts	Strong Buy
Price Target	63.15 (+128.39%)
Earnings Date	Mar 3, 2025

About BHVN

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 256
• Stock Exchange: NYSE
• Ticker Symbol: BHVN
• Website: https://www.biohaven.com

Analyst Forecast

According to 14 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is $63.15, which is an increase of 128.39% from the latest price.

Price Target

$63.15

(128.39% upside)

Analyst Consensus: Strong Buy